Complete remission in older acute myeloid leukemia: when does it really matter?

The therapeutic landscape of older acute myeloid leukemia (AML) has rapidly evolved with the introduction of venetoclax-based regimens, molecularly targeted therapies and improved transplant strategies. As complete remission (CR) becomes increasingly achievable in older patients, its actual contribution to long-term survival requires critical reassessment.

This review examines the biological, clinical and therapeutic determinants of CR in older AML, focusing on disease biology, hypomethylating agents-venetoclax combinations, IDH, FLT3 and menin inhibitors, intensive chemotherapy, allogeneic transplantation and the emerging concept of dynamic fitness. The literature was reviewed through a critical analysis of pivotal clinical trials, real-world studies, guideline recommendations and landmark translational investigations evaluating remission quality, measurable residual disease, treatment tolerability and survival outcomes.

In older AML patients, CR should no longer be regarded as a uniform therapeutic endpoint but as a multidimensional therapeutic state whose clinical value depends on disease biology, remission depth, preservation of patient fitness and the opportunity to deliver subsequent disease-modifying therapies. The future challenge in older AML is no longer simply to achieve complete remission, but to achieve the right remission--one capable of translating into meaningful long-term survival while preserving functional independence.